ESMO Congress

Toni Choueiri, MD, discusses KEYNOTE-564 subgroup findings, adjuvant pembrolizumab after nephrectomy, overtreatment risks, and emerging biomarkers in renal cell carcinoma.

Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.

Andrea Necchi, MD, discusses response-adapted treatment, higher complete response rates, and the potential to reduce the need for cystectomy and additional adjuvant therapy in muscle-invasive bladder cancer.

In OptimUM-01, first-line darovasertib plus crizotinib produced a 34.1% ORR and 21.1-month median OS in metastatic uveal melanoma, with activity across HLA subgroups.

At ESMO 2026, experts forecast how RAS inhibitors, new prostate cancer therapies, and IO combinations may reshape pancreatic, prostate, and endometrial care.

Necchi discusses the evolving role of ADC–immunotherapy combinations in muscle-invasive bladder cancer, chemotherapy after combination treatment, and the exception of tumors with small cell features.

Divarasib’s ORR was 58% vs 32% for sotorasib or adagrasib in the phase 3 Krascendo 1 trial. Dr Skoulidis discusses response, durability, and survival.

Dirk Schadendorf, MD, discusses where triplet therapy fits for BRAF V600-mutant melanoma following the results of the STARBOARD trial.

Ferdinandos Skoulidis, MD, PhD, explores emerging KRAS-targeted therapies in KRAS-mutated non–small cell lung cancer.

Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.

Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for first-line MSI-H/dMMR mCRC.

Nikhil I. Khushalani, MD, discusses outcomes of the HBI-8000-303 trial of a new combination in frontline advanced melanoma.

Daniel Heng, MD, MPH, FRCPC, discusses LITESPARK-011 and LITESPARK-012 data defining belzutifan's role in second-line and later advanced RCC.

The first-in-class oral RIPTAC molecule JNJ-6143 reached a 75% overall response rate and significant declines in PSA in metastatic castration-resistant prostate cancer.

Georgina V. Long, AO, BSc, PhD, MBBS, discusses the effort that goes into producing intismeran autogene neoantigen therapy tailored to each patient.

In an interview, David J. Benjamin, MD, explains the findings on gender makeup of NCCN guideline panels he presented at the 2026 ESMO Congress.

Lauren Banks, MD, PhD, discusses early lifileucel responses, safety findings, and next steps in the phase 2 SARATOGA trial for advanced soft tissue sarcoma.

Zev A. Wainberg, MD, MSc, reviews RASolute 302 findings on daraxonrasib's OS benefit across RAS genotypes in metastatic pancreatic cancer.

LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.

Bhavana Pothuri, MD, discusses TroFuse-005 at ESMO 2026, including TROP2 expression, treatment sequencing, and the future of endometrial cancer care.

Updated survival findings, perioperative treatment strategies, and circulating tumor DNA analyses highlight evolving approaches to genitourinary cancers.

Lauren Banks, MD, PhD, discusses TIL therapy feasibility and safety in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma.

Five ESMO 2026 abstracts report responses with 4 antibody-drug conjugates in ovarian cancer and a subcutaneous HER2-directed ADC plus PD-L1 inhibitor in cervical cancer.

Funda Meric-Bernstam, MD, discusses the outcomes of the FONTANA trial of an investigational folate receptor alpha–targeting antibody-drug conjugate in platinum-resistant ovarian cancer.

Late-breaking ESMO 2026 data show PFS gains with 3 antibody-drug conjugates, a 6-year OS benefit with adjuvant ribociclib, and no OS gain with pembrolizumab.

Phase 3 data at ESMO 2026: sac-TMT and iza-bren beat chemotherapy in NSCLC, while chemo plus pembrolizumab extended PFS in PD-L1–high disease.

Bhavana Pothuri, MD, discusses phase 3 TroFuse-005 data from ESMO, where sac-TMT improved PFS and OS vs chemotherapy in endometrial cancer.

Domenica Lorusso, MD, PhD, discusses phase 3 findings on sacituzumab tirumotecan in advanced or recurrent endometrial cancer.

ESMO 2026 Presidential Symposium III: ADC and immunotherapy highlights from the the ARTEMIS-011, TroFuse-005, KEYNOTE-C93, and MOIO trials.

Brian M. Slomovitz, MD, discusses the outcomes of the KEYNOTE-C93 trial of pembrolizumab for endometrial cancer.